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myloid-
 
 
 
 peptide (A
 
 
 
) accumulation in senile
plaques, a pathological hallmark of Alzheimer’s
disease (AD), has been implicated in neuronal degen-
eration. We have recently demonstrated that A
 
 
 
 induced
oligodendrocyte (OLG) apoptosis, suggesting a role in white
matter pathology in AD. Here, we explore the molecular
 
mechanisms involved in A
 
 
 
-induced OLG death, examining
the potential role of ceramide, a known apoptogenic
mediator. Both A
 
 
 
 and ceramide induced OLG death. In
addition, A
 
 
 
 activated neutral sphingomyelinase (nSMase),
but not acidic sphingomyelinase, resulting in increased
ceramide generation. Blocking ceramide degradation with
A
 
N
 
-oleoyl-ethanolamine exacerbated A
 
 
 
 cytotoxicity; and
addition of bacterial sphingomyelinase (mimicking cellular
nSMase activity) induced OLG death. Furthermore, nSM-
 
ase inhibition by 3-
 
O
 
-methyl-sphingomyelin or by gene
knockdown using antisense oligonucleotides attenuated
 
A
 
 
 
-induced OLG death. Glutathione (GSH) precursors
inhibited A
 
 
 
 activation of nSMase and prevented OLG
death, whereas GSH depletors increased nSMase activity
and A
 
 
 
-induced death. These results suggest that A
 
 
 
 induces
OLG death by activating the nSMase–ceramide cascade
via an oxidative mechanism.
 
Introduction
 
The amyloid-
 
 
 
 peptide (A
 
 
 
), a 39–43–amino acid cleavage
product of amyloid precursor protein (Estus et al., 1992;
Haass et al., 1992), has been implicated as the primary neu-
rotoxic factor in Alzheimer’s disease (AD) pathogenesis
(Yankner et al., 1989). In vitro, A
 
 
 
 is toxic to neurons
(Yankner et al., 1989; Behl et al., 1994; Yu et al., 1998),
endothelial cells (Thomas et al., 1996; Huang et al., 1998),
astrocytes (Brera et al., 2000), vascular smooth muscle cells
(Kawai et al., 1993; Davis-Salinas et al., 1995), and oligo-
dendrocytes (OLGs; Xu et al., 2001); and A
 
 
 
 depositions in
senile plaques are postulated to cause neuronal and vascular
degeneration in AD brains (Masters et al., 1985; Yankner et
al., 1989; Thomas et al., 1996). Although A
 
 
 
-mediated cell
 
death demonstrates morphological, biochemical, and molecular
features of apoptosis, the molecular mechanism underlying
A
 
 
 
 cytotoxicity remains largely undefined but may involve
oxidative stress (Behl et al., 1994; Schapira, 1996). NF-
 
 
 
B
and AP-1, redox-sensitive transcription factors, are activated
in A
 
 
 
-treated OLGs, and 
 
N
 
-acetylcysteine (NAC), an anti-
oxidant, prevents A
 
 
 
-mediated OLG apoptosis (Xu et al.,
2001). OLGs are susceptible to oxidative stress because they
have low levels of reduced glutathione (GSH) and high
concentrations of iron, resulting in a compromised ability to
scavenge peroxides (Thorburne and Juurlink, 1996; Back et
al., 1998; Juurlink et al., 1998).
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Ceramide, a lipid second messenger that increases the
cellular oxidative state, has been implicated in several
apoptosis paradigms including trophic factor withdrawal
and exposure to proinflammatory molecules (Coroneos
et al., 1995; Kyriakis and Avruch, 1996; Kolesnick and
Kronke, 1998). Cellular ceramide synthesis increases in re-
sponse to stress or death signals (Haimovitz-Friedman et
al., 1994; Tepper et al., 1995; Verheij et al., 1996). One
pathway of ceramide formation involves sphingomyelin
hydrolysis by either neutral sphingomyelinase (nSMase) or
acidic sphingomyelinase (aSMase; Testi, 1996); both en-
zymes are involved in several cell death paradigms (Ko-
lesnick and Kronke, 1998; Levade and Jaffrezou, 1999).
Another pathway involves ceramide synthase–catalyzed de
novo ceramide synthesis (Bose et al., 1995; Spiegel and
Merrill, 1996; Xu et al., 1998).
A
 
 
 
 and ceramide share cell death signaling characteris-
tics. A
 
 
 
-induced apoptosis involves TNF-
 
 
 
, p75 neu-
rotrophin receptor, and Fas ligand (Blasko et al., 1997; de
la Monte et al., 1997; Yaar et al., 1997), which are cell sur-
face receptors that relay death signals through the sphingo-
myelin–ceramide pathway (Dobrowsky et al., 1995; Han-
nun, 1996). Moreover, both A
 
 
 
 (Kaneko et al., 1995;
Askanas et al., 1996; Bruce-Keller et al., 1998; Xu et al.,
2001) and ceramide (Garcia-Ruiz et al., 1997; Singh et al.,
 
1998) cause mitochondrial dysfunction and induce oxi-
dative stress. In vitro, OLG death induced by A
 
 
 
 (Xu et
al., 2001) or ceramide (Larocca et al., 1997; Singh et
al., 1998; Scurlock and Dawson, 1999) share similar ap-
optotic characteristics. Lower sphingomyelin levels and
higher ceramide levels in AD brains have been reported
(Soderberg et al., 1992), thereby implying that increased
sphingomyelin degradation and ceramide accumulation
contribute to AD pathogenesis. We have previously shown
that A
 
 
 
 induced OLG death with characteristic features of
apoptosis (Xu et al., 2001). In this paper, we demonstrate
that ceramide mediates A
 
 
 
-induced OLG death by acti-
vating the nSMase–ceramide cascade.
 
Results
 
A
 
 
 
 and C2-ceramide are cytotoxic to OLGs
 
We have previously shown that A
 
 
 
 induced apoptosis in pri-
mary OLG cultures derived from neonatal rat brains, char-
acterized by nuclear and cytoskeletal disintegration, DNA
fragmentation, and mitochondrial dysfunction (Xu et al.,
2001). In this paper, we used neurosphere-derived differen-
tiated OLGs because of their ease of preparation compared
with primary OLG isolation. The neurosphere-derived dif-
ferentiated OLGs exhibited characteristic OLG morphol-
ogy, which is composed of large cell bodies with multiple
branching processes (Fig. 1, A–H). Immunocytochemical
analysis revealed that virtually all cells in culture expressed
four OLG-specific surface markers including cyclic nucle-
otide 3
 
 
 
-phosphodiesterase (Fig. 1 A, CNP), Rip (Fig. 1 C),
galactocerebroside (Fig. 1 E, GalC), and PLP (myelin pro-
teolipid protein; Fig. 1 G). In addition, differentiated OLGs
showed similar characteristic electrophysiological membrane
potentials (unpublished data) as reported in previous studies
(McDonald et al., 1999).
As demonstrated previously, A
 
 
 
 1-40 and A
 
 
 
 25-35 pep-
tides have equal potencies for inducing death in primary cul-
tures of OLGs (Xu et al., 2001); thus, most of our studies
were conducted using A
 
 
 
 25-35 with key experiments con-
firmed with A
 
 
 
 1-40. A
 
 
 
 25-35 treatment for 48 h caused
OLG death in a concentration-dependent manner with an
Figure 1. Characterization of OLG cultures. Immunofluorescent 
(A, C, E, and G) and corresponding phase-contrast (B, D, F, and H) 
photomicrographs of neurosphere-derived differentiated OLGs in 
culture. Cells demonstrate characteristic morphology of OLGs, 
plump cell body with multiple branching processes. Virtually all 
cells in culture immunostained for the OLG-specific antigens, CNP 
(A), Rip (C), GalC (E), and PLP (G). Bar, 30  m.
Figure 2. A  25-35 and C2-ceramide 
induced OLG death. (A) OLGs treated 
with 10–100  M A  25-35 for 48 h. 
(B) OLGs exposed to 10–100  M C2-
ceramide for 24 h. The assessment of 
cell survival based on MTT assay or cell 
death based on LDH assay showed a 
dose-dependent cytotoxic effect of A  
25-35 and C2-ceramide. Data shown are 
representative of three separate experi-
ments of triplicate samples with similar 
results; error bars represent SD. 
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approximate EC
 
50
 
 
 
 
 
 20 
 
 
 
M (Fig. 2 A). C2-ceramide, a cell-
permeable ceramide analogue, also induced dose-dependent
OLG death with an approximate EC
 
50
 
 
 
 
 
 30 
 
 
 
M (Fig. 2 B).
C2-dihydroceramide, a cell-impermeable and inactive form
of ceramide, was not cytotoxic at concentrations up to 100
 
 
 
M (unpublished data). The toxic effect of ceramide was
apparent at an earlier time point than that of A
 
 
 
 (Fig. 3, A
and B), raising the possibility that ceramide may be a media-
tor of A
 
 
 
-induced cell death.
 
Ceramide in A
 
 
 
 25-35–induced OLG death
 
To support the contention that ceramide is involved in A
 
 
 
-
induced OLG death, TLC and electrospray ionization/mass
spectrometry (ESI/MS) were used to measure ceramide con-
tent in OLGs with and without A
 
 
 
 treatment. A
 
 
 
 25-35
treatment resulted in a fivefold increase in ceramide synthesis
as determined by TLC (Fig. 4 A). An increase in cellular cer-
amide content was confirmed by ESI/MS, which demon-
strated peak ceramide content 10 h after A
 
 
 
 treatment (Fig.
4 B). 
 
N
 
-oleoyl-ethanolamine (NOE), a specific ceramidase
inhibitor that prevents the degradation of cellular ceramide at
subtoxic doses (Sugita et al., 1975; Pahan et al., 1998), aug-
mented A
 
 
 
 25-35–induced OLG death (Fig. 4 C). Together,
these results suggest a strong correlation between increases in
cellular ceramide levels and A
 
 
 
-induced OLG death.
 
nSMase activation in A
 
 
 
 25-35–induced OLG death
 
Ceramide is derived from sphingomyelin hydrolysis cata-
lyzed by nSMase or aSMase (Hannun, 1996). A
 
 
 
 25-35
treatment increased nSMase activity in OLGs as early as 2.5
min after exposure and reached maximal levels at 
 
 
 
16 h
(Fig. 5 A). A
 
 
 
 1-40 treatment also increased OLG nSMase
activity in a similar manner (unpublished data). In contrast,
A
 
 
 
 25-35 treatment did not alter aSMase activity (Fig. 5
A). The addition of recombinant bacterial sphingomyelin-
ase (bSMase), an exogenous source of sphingomylinase that
mimics nSMase action by degrading membrane sphingo-
myelin to increase cellular ceramide levels (Okazaki et al.,
1989; Jarvis et al., 1994; Zhang et al., 1997; Tonnetti et
al., 1999), caused OLG death (Fig. 5 B). Furthermore, the
nSMase inhibitors, 3-
 
O
 
-methyl-sphingomyelin (3-OMe-
SM; Lister et al., 1995) and NAC (Liu et al., 1998a; Yoshi-
mura et al., 1999), were effective in protecting OLGs against
A
 
 
 
 cytotoxicity (Fig. 5, C and D). Confirming the effects
of the nSMase inhibitors, a marked reduction in nSMase
enzymatic activity was observed in OLGs treated with
3-OMe-SM or NAC (Fig. 6 A). Moreover, significant de-
creases in endogenous ceramide content and increases in
sphingomyelin levels were detected in OLGs treated with
the inhibitors (Fig. 6, B and C). To further confirm the
contribution of nSMase in A
 
 
 
-mediated cell death, sense
and antisense oligonucleotides specific for nSMase were
generated. Antisense oligonucleotides reduced nSMase ac-
tivity (Fig. 7 A), reduced ceramide content in cell lysates
(Fig. 7 B), and attenuated A
 
 
 
-induced cell death (Fig. 7 C),
but sense oligonucleotides had no effect on nSMase activ-
ity, ceramide content, or cell survival.
Figure 3. Time-dependent cell death 
induced by A  25-35 and C2-ceramide. 
(A) Cell survival as measured by MTT 
assay. (B) Cell death as determined by 
LDH assay. OLGs were treated with 20 
 M A  25-35 or 30  M C2-ceramide for 
the time periods indicated. The cells and 
culture medium were used for the MTT 
or LDH assay, respectively. Note the 
faster pace of ceramide in inducing OLG 
death, 50% OLG death was noted 24 
and 48 h after ceramide and A  treat-
ment, respectively. Data shown are 
representative of three separate experi-
ments of triplicate samples with similar 
results; error bars represent SD.
Figure 4. A  25-35–induced ceramide production and enhancement 
of A  cytotoxicity by a ceramidase inhibitor. (A) An increase in 
cellular ceramide synthesis in OLGs prelabeled with [
3H]palmitate 
and treated with 10  M A  25-35 for 24 h. (B) Quantitative deter-
mination of endogenous ceramide concentration by ESI/MS at 
various time points after A  25-35 treatment. Note the elevated 
ceramide content at 5, 10, and 16 h after A  25-35 exposure. (C) Effect 
of NOE, a ceramidase inhibitor, on A -induced OLG death. OLGs 
were treated with 10  M A  25-35 plus 1  M NOE for 24 h. The 
culture medium was collected for the LDH assay. Data shown are 
mean   SD of three separate experiments in triplicate. *, Significant 
difference from control; **, significant difference from A  treatment; 
P   0.05.126 The Journal of Cell Biology | Volume 164, Number 1, 2004
It has been shown that A  depletes GSH in cortical neu-
rons in vitro (Muller et al., 1997), which correlates well
with the ability of A  to heighten cellular oxidative stress
(Cafe et al., 1996). GSH depletion has been shown to acti-
vate nSMase activity (Liu and Hannun, 1997; Liu et al.,
1998a,b). The fact that NAC, a GSH precursor, inhibited
A  25-35 activation of nSMase and prevented A -medi-
ated OLG death suggests that A  25-35 depletion of cellu-
lar GSH is involved in the A –nSMase–ceramide OLG
death signaling cascade. Buthionine sulfoximine (BSO)
and diethyl maleate (DEM) have been shown to deplete
GSH in various cell types (Anderson and Meister, 1983;
Masukawa et al., 1983; Szekely and Lobreau, 1987). Both
BSO and DEM selectively increased nSMase activity (Fig.
8 A), increased ceramide levels (Fig. 8 B), decreased cellu-
lar GSH levels (Fig. 8 C), and were cytotoxic to OLGs
(Fig. 8 D).
Because A  25-35 did not activate aSMase, it is unlikely
that aSMase is involved in A  25-35–induced OLG death.
Selective aSMase inhibitors such as desipramine and chlor-
promazine (Albouz et al., 1986) were ineffective in protect-
ing OLGs from A  25-35–induced death (unpublished
data). Furthermore, fumonisin B2, a ceramide synthase in-
hibitor, did not block A  25-35 cytotoxicity in this cell
death paradigm (unpublished data). Together, these results
suggest that ceramide generation catalyzed by nSMase, but
not aSMase or ceramide synthase, mediates the A  25-35
death pathway in OLGs.
Discussion
Several lines of evidence support the contention that cer-
amide mediates, at least in part, A -induced OLG death.
Both A  and C2-ceramide (but not the biologically inactive
dihydroceramide) caused OLG death in a time-dependent
manner. A  treatment increased ceramide formation in
OLGs. In addition, increasing cellular ceramide release from
sphingomyelin by exogenous bSMase, which mimics cellular
nSMase action, also induced OLG death. Inhibition of cer-
amide degradation by NOE, a ceramidase inhibitor, en-
hanced A  cytotoxicity in OLGs.
Results from this study also support the contention that A 
cytotoxicity is mediated via activation of nSMase leading to
increased cellular ceramide generation. A  25-35 and A 
1-40 activated nSMase, but not aSMase, in OLGs. Addition-
Figure 5. Sphingomyelinase in A -induced OLG death. (A) nSMase 
and aSMase activity in OLGs treated with 10  M A  25-35 for 
various time periods (from 2.5 min to 36 h). (B) A  or bSMase 
induced OLG death as determined by LDH assay. OLGs were 
exposed to 10  M A  25-35 or bSMase (1 U/ml) for 24 h. (C) LDH 
and (D) trypan blue assays on the effects of nSMase inhibitors on 
A -mediated OLG death. OLGs were treated with 25 mM NAC or 1 
 M 3-OMe-SM for 2 h before 10  M A  25-35 treatment for 24 h. 
Data shown are representative of three separate experiments of 
triplicate samples with similar results; error bars represent SD. *, 
Significant difference from control; **, significant difference from 
A  treatment; P   0.05.
Figure 6. Effect of nSMase inhibitors on sphingomyelinase activity 
and ceramide/sphingomyelin content in A  25-35–treated OLGs. 
nSMase and aSMase activity (A) and cellular ceramide (B) and 
sphingomyelin (C) content in OLGs treated with NAC or 3-OMe-SM 
nSMase inhibitors. OLGs were treated with 1  M 3-OMe-SM or 25 
mM NAC for 2 h before 10  M A  25-35 exposure for 16 h. Repre-
sentative TLC data are shown from one of three experiments in the 
top panels in B and C. A and the bottom panels in B and C show 
composite results from three separate experiments; error bars 
represent SD. *, Significant difference from control; **, significant 
difference from A  treatment; P   0.05.A  cytotoxicity mediated by the ceramide pathway | Lee et al. 127
ally, nSMase inhibitors such as 3-OMe-SM and NAC (also
an antioxidant) prevented A  25-35–induced nSMase activ-
ity, which resulted in decreased ceramide synthesis from
sphingomyelin and protected OLGs from A  25-35 cytotox-
icity. Antisense oligonucleotides specific for nSMase also
attenuated A -induced OLG cell death, further implicating
nSMase as a mediator. Chemical agents such as BSO and DEM
that deplete cellular GSH content also activated nSMase in
OLGs and caused cell death. The specific role of nSMase in
A -induced OLG death is supported by the finding that
pharmacological inhibition of nSMase, but not aSMase
or ceramide synthase, prevented A  25-35–induced OLG
death.
The exact mechanism underlying A -mediated nSMase ac-
tivation remains to be elucidated but may involve changes in
the cellular redox state and/or GSH metabolism (Sawai and
Hannun, 1999); GSH is the most abundant thiol-containing
compound in living cells. nSMase enzymatic activity is di-
rectly regulated by cellular GSH content (Liu and Hannun,
1997; Liu et al., 1998a,b). A  has been shown to deplete
GSH in cultured cortical neurons (Muller et al., 1997), and
depletion of cellular GSH stores by oxidative stress has been
proposed as a prime mechanism underlying the A  cytotoxic
action (Muller et al., 1997; Pereira et al., 1999). Thus, it is
plausible that a decrease in GSH level subsequent to A  expo-
sure may activate nSMase in OLGs. NAC, a GSH precursor,
inhibited A  25-35 activation of nSMase and protected
OLGs against A -induced death, whereas depletion of cellu-
lar GSH stores by BSO or DEM resulted in selective activa-
tion of nSMase and OLG death. Although the agents used to
manipulate GSH levels may be relatively nonspecific, these
findings raise the possibility that the activation of nSMase by
A  may involve the depletion of cellular GSH content.
Oxidative stress plays a prominent role in A -mediated
neuronal and OLG death (Behl et al., 1994; Behl, 1999;
Markesbery, 1999; Xu et al., 2001). Brain tissue is especially
sensitive to oxidative injury because of its higher metabolic
rate driven by glucose, lower concentrations of protective
antioxidants, and higher levels of polyunsaturated fatty acids
that are susceptible to lipid peroxidation (Behl and Sagara,
1997; Behl, 1999; Markesbery, 1999). Although A -medi-
ated oxidative stress induces mtDNA damage (Bozner et al.,
1997; Xu et al., 2001) and activates selected transcription
factors including NF- B and AP-1 (Abate et al., 1990;
Schreck et al., 1991; Pinkus et al., 1996; Xu et al., 2001),
the mechanism by which A  induces oxidative stress in the
AD brain remains unknown. Ceramide has emerged as a po-
tent second messenger in oxidative stress-induced apoptosis
(Hannun and Luberto, 2000). Hydrogen peroxide (Gold-
korn et al., 1998), 1- -D-arabinofuranosylcytosine (Brad-
shaw et al., 1996), daunorubicin (Jaffrezou et al., 1996),
TNF-  (Bezombes et al., 1998),  -rays (Bruno et al., 1998),
hypoxia (Yoshimura et al., 1998), CD40 activation (Segui et
al., 1999), and sindbis virus infection (Jan et al., 2000) are
among the agents that can mediate cell death via nSMase ac-
tivation, thus emphasizing the central role of the nSMase–
ceramide cascade. Results shown here provide a unique sig-
naling pathway from cell surface A  engagement, induction
Figure 7. Treatment of OLGs with nSMase antisense oligonucleo-
tides. OLGs were treated with sense or antisense oligonucleotides 
specific for nSMase 4 h before 20  M A  addition. After 24 h, the 
cells were harvested and assayed for nSMase activity (A), ceramide 
content (B), and MTT (C). The graph depicts a representative of three 
separate experiments with similar results; error bars represent SD. *, 
Significant differences compared with A  treatment alone; P   0.05.
Figure 8. Effects of GSH depleting 
agents compared with A  25-35 on 
sphingomyelinase activity, cellular GSH 
content, and cell survival. OLGs were 
treated with 10  M A  25-35, 100  M 
BSO, or 500  M DEM for 16 h before 
measurement of sphingomyelinase 
activity (A), ceramide synthesis (B), or 
GSH content (C), or 24 h before MTT 
assay (D). Data shown in A, C, and D 
are representative of three separate ex-
periments of triplicate samples and, in B, 
of two separate experiments with similar 
findings; error bars represent SD. *, 
Significant difference from control; 
P   0.05.128 The Journal of Cell Biology | Volume 164, Number 1, 2004
of oxidative stress, and activation of the nSMase–ceramide
cascade culminating in OLG death.
In summary, this work demonstrates a novel mechanism
for A -induced OLG death. These results reveal a causal re-
lationship between A  exposure and the activation of the
nSMase–ceramide pathway, which is likely to involve
heightened oxidative stress after depletion of cellular GSH
stores. In addition, we have evidence that activation of
the nSMase–ceramide cascade may also contribute to A -
induced death of cortical neurons and cerebral endothelial
cells (unpublished data), thereby suggesting that this cascade
may be operating in many cell types other than OLGs.
A →nSMase→ceramide cascade represents a novel signal-
ing pathway that contributes at least in part to A  cytotoxic-
ity to various types of brain cells. Identification of this
pathway may lead to the development of more effective
therapeutic strategies aimed at preventing A -induced cell
death. For instance, blockade of the A -activated death sig-
naling process can be achieved by pharmacological modula-
tion of nSMase activity as demonstrated in this work.
Materials and methods
Reagents and cell culture
All chemicals were purchased from Sigma-Aldrich, and all cell culture re-
agents were purchased from Invitrogen unless otherwise specified. B104
cells (a gift from David Schubert, Salk Institute for Biological Studies, La
Jolla, CA) were cultured in DME supplemented with 10% FBS, 100 U/ml
penicillin, and 100  g/ml streptomycin.
OLG culture
Neurospheres were cultured using the methods of Zhang et al. (1999) with
modifications. In brief, embryonic rat brains (E14–16 d) were dissected,
homogenized gently in DME/Ham’s F12, and centrifuged at 350 g for 5
min. The pellet was digested with 0.05% trypsin in 1.5 ml of 0.53 M EDTA
for 30 min at 37 C, followed by the addition of 1.5 ml DME/Ham’s F12
with 20% FBS, and filtered through 10- m nylon mesh. The filtrate was
centrifuged at 350 g for 5 min, and the pellet was washed twice with DME/
Ham’s F12. Dissociated cells were layered on a preequilibrated Percoll
gradient (formed by centrifuging 50% Percoll and 50% DME/Ham’s F12 at
23,500 g for 1 h at 4 C) and centrifuged at 3,500 g for 15 min. The fraction
containing glial progenitors banding between myelin and blood cell layers
was recovered and washed twice with DME/Ham’s F12 followed by an-
other wash with neurosphere culture medium (DME/Ham’s F12/Hepes, N1
supplement, 25  g/ml insulin, 130 ng/ml progesterone, 20 ng/ml of basic
FGF, and 20 ng/ml EGF). The cell pellet was resuspended in 20 ml of neu-
rosphere culture medium and seeded in 75-mm culture flasks. After 24 h,
when neurospheres had formed, 5 ml of fresh medium was added to each
culture every other day for 7 d, and then the neurosphere cultures were
split (1:2). The neurospheres were dissociated gently 10 times with a sy-
ringe and a 25-gauge needle and centrifuged at 350 g. The resulting cell
pellets were treated with 0.05% trypsin/0.53 mM EDTA and centrifuged at
350 g for 10 min. The cells were resuspended in progenitor medium (69%
DME/Ham’s F12/Hepes containing N1 supplement, 10  g/ml insulin, 20
nM progesterone, 30% conditioned medium from B104 cells, and 1% FBS)
and plated on 100-mm culture dishes precoated with poly-L-ornithine. For
differentiated OLG cultures, progenitor cells were detached with trypsin/
EDTA and cultured on poly-L-ornithine–coated plates or coverslips in ma-
ture OLG medium (DME/Ham’s F12; N1 supplement, 20  g/ml biotin; 20
 g/ml triiodo-L-thyronine, T3, and 1% FBS).
Immunocytochemistry
Differentiated OLG cultures were fixed in 4% PFA, washed in PBS, and
blocked with 5% goat serum. Fixed cells were incubated with the primary
antibody overnight at 4 C. The following primary antibodies were used:
anti–mouse CNP, anti–mouse Rip, anti–mouse PLP (Chemicon), and anti–
mouse GalC (Cedarlane Laboratories) at a concentration of 1:100. The
secondary antibody, anti–mouse IgG conjugated to FITC (Vector Laborato-
ries), was added for 1 h at RT. The cells were washed in PBS and visual-
ized using a confocal microscope (model LSM 5 Pascal; Carl Zeiss
MicroImaging, Inc.) equipped with a CCD camera (model Axiocam HR;
Carl Zeiss MicroImaging, Inc.). Images were collected and processed using
Adobe Photoshop software.
Sphingomyelinase assay
The cells were washed twice with PBS, pH 7.4, and lysed in 0.2% Triton
X-100 for 10 min at 4 C. The lysates were sonicated for 30 s in ice-cold bath,
and protein concentrations were determined by Lowry assay (Lowry et al.,
1951). A sphingomyelinase substrate, [methyl-
14C]sphingomyelin (55 mCi/
mmol; Amersham Biosciences), was evaporated to dryness and resuspended
in either 25  l of nSMase assay buffer (40 mM Hepes, 5 mM MgCl2, and
0.2% Triton X-100, pH 7.4) or aSMase assay buffer (250 mM sodium acetate
and 0.2% Triton X-100, pH 5.2) and sonicated to form micelles on ice until
use. Each reaction containing 25  l of cell lysate protein (1 mg/ml) and 25
 l [methyl-
14C]sphingomyelin (0.23 nmol) in nSMase or aSMase assay buffer
was incubated for 2 h at 37 C. The reaction was terminated with 200  l
CHCl3/methanol (1:1) and 90  l H2O followed by vigorous agitation. The
samples were centrifuged at 6,000 g for 5 min. [
14C]Phosphocholine in the
aqueous phase (120  l) was collected for liquid scintillation counting. Phos-
phocholine is the degraded moiety of sphingomyelin after ceramide is re-
leased by nSMase or aSMase. The aSMase or nSMase activity was calculated
as picomoles of sphingomyelin hydrolyzed by 1 mg of total proteins per
hour and expressed as a percentage of control values.
TLC
OLGs with or without A  25-35 treatment were cultured with 10  Ci
[
3H]palmitate (1 mCi/ml; Amersham Biosciences; Kaneko et al., 1995). The
labeled cells were collected and washed twice with PBS, pH 7.4, to re-
move free isotope before lipid extraction (Xu et al., 1998). The cell pellet
was resuspended in 400  l methanol/1 N HCl (100:6, vol/vol) followed by
800  l chloroform and 240  l H2O. The sample was mixed and centri-
fuged at 6,000 g for 5 min. The lipid fraction was reextracted with 1 ml
chloroform/methanol (2:1, vol/vol) and applied to a TLC plate. The solvent
was chloroform/methanol/acetic acid/H2O (85:4.5:5:0.5, vol/vol) for cer-
amide and chloroform/methanol/acetic acid/water (65:25:8.8:4.5, vol/vol)
for sphingomyelin. Plates were air dried and sprayed with 1 M sodium sa-
licylate for autoradiography. Standard lipids were stained by rhodamine
6G (Sigma-Aldrich) and visualized by UV light.
Quantitative ceramide analysis by ESI/MS
After three washes with PBS, pH 7.4, OLGs harvested from 100-mm cul-
ture plates with or without A  25-35 treatment were homogenized in 0.5
ml PBS, pH 7.4, with a glass tissue grinder. A bicinchomic protein assay kit
was used to determine the protein concentration before lipid extraction
(Pierce Chemical Co.). Lipids from the homogenates were extracted as de-
scribed previously with modifications (Bligh and Dyer, 1959) using 50 mM
LiOH in the aqueous layer and C17:0 ceramide (2 nmol/mg protein) as an
internal standard for quantitation of ceramide content. These molecular
species represent  1% of the endogenous cellular lipid mass. The lipid ex-
tracts were dried under a nitrogen stream, dissolved in chloroform, de-
salted with Sep-Pak columns, and filtered with 0.2  m PTFE syringe filters
(Fisher Scientific). Lipids were reextracted with 20 mM LiOH in the aque-
ous layer, dried under a nitrogen stream, and resuspended in 0.5 ml of
chloroform/methanol (1:1, vol/vol) for ESI/MS analysis.
ESI/MS analysis was performed using a spectrometer (model TSQ-7000;
Finnigan) equipped with an electrospray ion source as described previ-
ously (Han et al., 1996, 2001). A 5-min period of signal averaging in the
profile mode was used for each spectrum of a lipid extract. All extracts
were directly infused into the ESI chamber using a syringe pump at 1  l/
min flow rate. Ceramide in the lipid extracts was quantitated directly as
deprotenated ions ([M-H]
 ) in comparison with an internal standard (C17:0
ceramide) after correction for 
13C isotope effects in the negative-ion mode.
Ion peaks were identified using tandem mass spectroscopic analyses as de-
scribed previously (Han and Gross, 1995).
Cell death assays
OLG viability was quantitated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay and trypan blue exclusion method.
Cell death was also assessed by the amount of lactate dehydrogenase
(LDH) release into the culture medium after A  or C2-ceramide treatment
(Koh and Choi, 1987; Shaikh et al., 1997; Xu et al., 1998). The amount of
LDH released by cells killed with Triton X-100 was considered maximal
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Assay for cellular GSH content
Cellular GSH levels were determined using a GSH-400 colorimetric assay
kit (Calbiochem-Novabiochem). Triplicate samples (3   10
6 cells) were col-
lected by centrifugation and washed twice with PBS, pH 7.4. The cell pel-
lets were treated with 5% metaphosphoric acid (Sigma-Aldrich). A Teflon
pestle was used to homogenize the cells. Protein concentrations were deter-
mined by Lowry assay (Lowry et al., 1951). The homogenates were centri-
fuged at 3,000 g for 10 min at 4 C. Supernatants were assayed for GSH ac-
cording to the instructions provided with the kit. A standard curve was
generated with graded concentrations of GSH (5–40  M). GSH concentra-
tion was measured by absorbance at 400 nm with a spectrophotometer.
nSMase antisense oligonucleotides
Morpholino sense (GCCGCAGAGAAAAGTTGTGCTTCAT) and antisense
(CCTCTTACCTCAGTTACAATTTATA) oligonucleotides were generated for
nSMase (Gene Tools, LLC). OLGs in serum-free medium were treated with
1.4  M oligonucleotides in EPEI delivery solution (per manufacturer’s in-
structions; Gene Tools) for 4 h. The medium was exchanged and A  was
added for 24 h, after which cells were harvested for nSMase activity or cell
death determination.
Statistical analysis
Results are expressed as mean   SD. Differences among groups were ana-
lyzed by one-way ANOVA followed by Bonferroni’s post-hoc t test to de-
termine statistical significance. Comparison between two experimental
groups was based on two-tailed t test. P   0.05 was considered statistically
significant.
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